Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.

United States Food and Drug Administration (FDA) approvals of immunotherapy for the second-line treatment of advanced NSCLC in 2015 were associated with increased rates of any second-line treatment, but disparities based on social determinants of health persisted.